Accel Research Sites
Accel Research Sites (dba Alcanza Clinical Research) operates a 26+ location network of multi-therapeutic clinical research sites across the US and Puerto Rico, serving pharmaceutical sponsors and CROs with patient recruitment, trial execution, and the ReachOne AI Toolbox.
- Company typePrivate
- Founded1998
- HeadquartersFlorida, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Accel Research Sites does
Accel Research Sites, doing business as Alcanza Clinical Research, is a private clinical research site network founded in 1998 and headquartered in Florida. The company operates 26+ dedicated clinical research facilities across the Southeast, Northeast, Midwest, and Southwest United States, plus Puerto Rico (Mayagüez and San Juan), providing trial execution services in more than 30 therapeutic areas including Alzheimer's disease, oncology, diabetes, vaccines, dermatology, cardiology, and women's health. Accel serves two primary customer segments: pharmaceutical sponsors and Contract Research Organizations (CROs), which contract the network to conduct clinical trials; and patient volunteers, who are recruited through a community-based GTM model that combines website registration, medical provider referrals, and outreach to community-based organizations. The company emphasizes inclusive research participation across diverse demographic populations, supported by multilingual website access in eight languages (English, Spanish, French, German, Italian, Dutch, Chinese, and Arabic).
The company's core technology is the ReachOne AI Toolbox, a wholly-owned subsidiary product positioned as an AI-powered platform for clinical research operations with integration/interoperability as its cited differentiator. ReachOne supplements the primary professional-services revenue stream, which is generated through per-study fees from sponsors and CROs for patient recruitment, study execution, and data collection. Accel is a founding member of the Association of Multisite Research Corporations (AMRC), launched in 2024 as a 14-organization alliance encompassing 400+ research sites, nearly 1,000 Principal Investigators, and more than 7,000 research professionals that collectively enrolled over 73,500 patients in 2024. No external funding rounds, M&A activity, or institutional ownership are disclosed in the available source material, and the company appears to operate as an independently-run private entity.
Accel Research Sites firmographics
Firmographics- Name
- Accel Research Sites
- Legal name
- Accel Research Sites
- Website
- https://accelresearchsites.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Accel Research Sites (dba Alcanza Clinical Research) operates a 26+ location network of multi-therapeutic clinical research sites across the US and Puerto Rico, serving pharmaceutical sponsors and CROs with patient recruitment, trial execution, and the ReachOne AI Toolbox.
- Ownership category
- akta.pro rank
Where Accel Research Sites is headquartered
LocationHeadquarters
- HQ city
- Florida
- HQ country
- United States
- HQ region
- North America
Offices31 records
Markets served
Accel Research Sites business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Clinical Research Services: Revenue generated from conducting clinical trials on behalf of pharmaceutical sponsors and Contract Research Organizations (CROs). Services include patient recruitment, study execution, and data collection for drug development programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Patient volunteer compensation for participation |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Accel Research Sites product offering
Product offeringCore offering
Accel Research Sites (operating as Alcanza Clinical Research) is a multi-therapeutic network of dedicated clinical research sites that conduct clinical trials on behalf of pharmaceutical sponsors and Contract Research Organizations (CROs). The company delivers patient recruitment, study execution, and data collection services across a broad range of therapeutic areas, including Alzheimer's, diabetes, vaccines, oncology, and chronic conditions, through a community-based model spanning 26+ dedicated research facilities across the United States and Puerto Rico.
Product overview
Alcanza Clinical Research operates as a clinical research site network offering a unified platform for clinical trial participation. The core product is their clinical research services network, supplemented by the ReachOne AI Toolbox for technology-enabled research capabilities. They provide local communities with opportunities to participate in clinical research at dedicated facilities across multiple states, collaborating with medical providers and community organizations.
Differentiator
Problem solved
Functional benefit
Brands
- ReachOne AI Toolbox: AI-powered clinical research tools and platform technology
Products and services
- Alcanza Clinical Research Clinical research site network providing health education and clinical research participation options to diverse patient populations across multiple therapeutic areas. Operates dedicated clinical research facilities across the United States and Puerto Rico, collaborating with medical providers and community-based organizations to deliver clinical trial opportunities for pharmaceutical sponsors and CROs.
Quantifiable outcome
- 73,500 patients enrolled in clinical trials in 2024 through AMRC network
Companies that use Accel Research Sites
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Accel Research Sites technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Accel Research Sites partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Association of Multisite Research Corporations (AMRC)coreAlcanza Clinical Research is a founding member of AMRC, a newly launched alliance of 14 prominent multisite research organizations. AMRC aims to transform clinical trial operations across the U.S. with a network of over 400 research sites, nearly 1,000 Principal Investigators, and over 7,000 research professionals. In 2024, AMRC members collectively enrolled over 73,500 patients into clinical trials. The alliance focuses on minimizing delays impacting 80% of clinical trials, improving operational efficiency, and strengthening collaboration and data quality.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Accel Research Sites competitors and assessment
Company assessmentDirect peers
- Flourish Research: Multisite clinical research organization operating dedicated research facilities with multi-therapeutic enrollment. Directly comparable SMO competing in the same sponsor-RFP environment as Accel Research Sites.
- Velocity Clinical Research: Multi-therapeutic integrated clinical research site network operating dedicated research facilities across the US. Directly comparable to Accel on SMO business model, multi-therapeutic scope, geographic dispersion, and sponsor/CRO customer base.
- Worldwide Clinical Trials: Mid-size global CRO with site-management and clinical operations offerings. Comparable to Accel on customer base (small-to-mid-biotech sponsors), therapeutic breadth, and professional-services revenue model.
- Clinipace Worldwide: Mid-size full-service CRO with embedded site management capabilities, serving similar small-to-mid-biotech sponsors as Accel. Comparable on therapeutic scope, sponsor-customer profile, and clinical operations delivery model.
- Centricity Research: Integrated multi-specialty clinical research site organization running dedicated Phase I-IV sites across North America. Closely comparable to Accel in site-network model, therapeutic breadth, and AMRC-era multisite positioning.
Broad incumbents
- ICON plc: Global CRO with site-management, clinical operations, and lab services at scale. Competes head-to-head with Accel for site-network selection on multi-region sponsor trials, though from a much broader service portfolio.
- Medpace: Mid-to-large CRO specializing in operational delivery of clinical trials across therapeutic areas. Comparable on the clinical-operations and Phase II/III execution layer where Accel provides site capacity, but operates without a dedicated owned-site footprint of Accel's scale.
- IQVIA: Largest global CRO with an integrated site-management and clinical operations platform. Overlaps with Accel on clinical research service delivery but competes from full-service portfolio leverage — directly bidding against Accel for sponsor master agreements.
- Parexel International: Global CRO offering clinical operations, site management, regulatory, and biopharma services. Comparable to Accel on the sponsor-customer side and on clinical trial execution, though from a far broader full-service delivery model.
- Syneos Health: Global CRO with embedded site-network and decentralized-trial capabilities. Comparable across clinical operations and site management, broader portfolio across commercial and consulting services beyond Accel's narrower SMO scope.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Accel Research Sites financial estimates
Financial estimateRevenue estimate
Valuation estimate
Accel Research Sites leadership team
Management profileNumber of profiles
Accel Research Sites subsidiaries and ownership
Company hierarchySubsidiaries1 record
Accel Research Sites funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Accel Research Sites M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Accel Research Sites
What does Accel Research Sites do?
Accel Research Sites (operating as Alcanza Clinical Research) is a multi-therapeutic network of dedicated clinical research sites that conduct clinical trials on behalf of pharmaceutical sponsors and Contract Research Organizations (CROs). The company delivers patient recruitment, study execution, and data collection services across a broad range of therapeutic areas, including Alzheimer's, diabetes, vaccines, oncology, and chronic conditions, through a community-based model spanning 26+ dedicated research facilities across the United States and Puerto Rico.
Is Accel Research Sites a public or private company?
Accel Research Sites is a private company. It is classified as unknown and is currently operating.
When was Accel Research Sites founded?
Accel Research Sites was founded in 1998. It employs 51 to 100 people.
Where is Accel Research Sites based?
Accel Research Sites is headquartered in Florida, United States, in the North America region.
How does Accel Research Sites make money?
One revenue line is on record: clinical Research Services.
Who are Accel Research Sites's main competitors?
Direct peers on record are Flourish Research, Velocity Clinical Research, Worldwide Clinical Trials, Clinipace Worldwide and Centricity Research. Broad incumbents are ICON plc, Medpace, IQVIA, Parexel International and Syneos Health.
Does Accel Research Sites have an API?
No public API is recorded for Accel Research Sites.